Holen Sie sich die Stockscreener-App
3.0366
1.62%
-0.0434
Schlusskurs vom Vortag:
$3.08
Offen:
$3.11
24-Stunden-Volumen:
1.77M
Relative Volume:
0.73
Marktkapitalisierung:
$274.26M
Einnahmen:
$32.31M
Nettoeinkommen (Verlust:
$-237.09M
KGV:
-1.0544
EPS:
-2.88
Netto-Cashflow:
$-219.11M
1W Leistung:
-6.77%
1M Leistung:
-22.70%
6M Leistung:
+84.76%
1J Leistung:
+4.12%
1-Tages-Spanne:
$2.87
$3.11
1-Wochen-Bereich:
$2.87
$3.365
52-Wochen-Spanne:
$0.9101
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Vergleichen Sie EDIT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
3.05 | 276.95M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.24 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.54 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.50 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
825.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.20 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Can Editas Medicine Inc. stock sustain market leadershipJuly 2025 Market Mood & AI Based Buy/Sell Signal Reports - newser.com
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 - The Manila Times
Editas Medicine unveils EDIT-401 data at AHA 2025 - Traders Union
Editas Medicine Announces EDIT-401 Poster Presentation at - GlobeNewswire
Will Editas Medicine Inc. stock continue upward momentumWeekly Volume Report & High Yield Equity Trading Tips - newser.com
Should you hold or exit Editas Medicine Inc. nowTreasury Yields & Long-Term Growth Plans - newser.com
Can Editas Medicine Inc. stock weather global recessionMarket Performance Summary & Verified Momentum Stock Alerts - newser.com
Backtesting results for Editas Medicine Inc. trading strategiesJuly 2025 Action & Free Growth Oriented Trading Recommendations - newser.com
Should I hold or sell Editas Medicine Inc. stock in 2025Portfolio Return Report & Weekly High Momentum Picks - newser.com
What moving averages say about Editas Medicine Inc.July 2025 Short Interest & Risk Controlled Daily Plans - newser.com
Institutional scanner results for Editas Medicine Inc.Dip Buying & Stepwise Trade Signal Implementation - newser.com
Combining price and volume data for Editas Medicine Inc.Wall Street Watch & Risk Managed Investment Signals - newser.com
How Editas Medicine Inc. (8EM) stock valuation compares with sector2025 Key Highlights & Entry Point Confirmation Alerts - newser.com
Why analysts raise outlook for Editas Medicine Inc. (8EM) stock2025 Dividend Review & Community Consensus Trade Signals - newser.com
Is Editas Medicine Inc. stock a smart buy before Fed meetingJuly 2025 Earnings & Real-Time Volume Analysis - newser.com
How Editas Medicine Inc. (8EM) stock responds to job market shiftsGlobal Markets & Daily Price Action Insights - newser.com
Why analysts remain bullish on Editas Medicine Inc. stockJuly 2025 Setups & AI Powered Market Entry Ideas - newser.com
Is Editas Medicine Inc. stock attractive after correctionMarket Activity Report & Consistent Profit Trading Strategies - newser.com
How currency fluctuations impact Editas Medicine Inc. stockPortfolio Gains Report & Weekly Market Pulse Alerts - newser.com
Can Editas Medicine Inc. stock sustain institutional interestJuly 2025 PostEarnings & High Yield Stock Recommendations - newser.com
How to build a dashboard for Editas Medicine Inc. stockWeekly Risk Summary & AI Enhanced Trading Signals - newser.com
Editas Medicine’s Long-Term Study on EDIT-301: A Potential Game-Changer for Hemoglobinopathies - TipRanks
Can Editas Medicine Inc. stock withstand economic slowdownOil Prices & High Conviction Buy Zone Alerts - newser.com
How institutional ownership impacts Editas Medicine Inc. stockJuly 2025 Volume & Community Verified Trade Signals - newser.com
Is Editas Medicine Inc. (8EM) stock expanding market penetrationJuly 2025 Analyst Calls & Daily Profit Maximizing Trade Tips - newser.com
Full technical analysis of Editas Medicine Inc. stockPortfolio Performance Summary & Capital Protection Trading Alerts - newser.com
Does Editas Medicine Inc. qualify in momentum factor screeningPortfolio Update Report & Weekly Setup with High ROI Potential - newser.com
Will Editas Medicine Inc. stock beat EPS estimates2025 Biggest Moves & Precise Entry and Exit Recommendations - newser.com
Editas Medicine Stock Fell 13% in a Day, What Now? - Trefis
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):